Clinically actionable information with a simple blood draw – The OncoBEAM™ RAS CRC KIT!
Go beyond KRAS – The All-RAS-Panel
Recent clinical studies have shown that the detection of additional mutations in KRAS and NRAS codons should also be considered in determining patient eligibility for targeted anti‐EGFR therapies. The OncoBEAM™ RAS qualitative digital PCR based test is intended for the detection of gene mutations in KRAS codons 12, 13, 59, 61, 117, 146 and NRAS codons 12, 13, 59, 61, 117, 146 extracted from Stage IV colorectal cancer patient plasma. The kit is intended to aid the clinician in determining potential benefit of anti-epidermal growth factor receptor (EGFR) therapy to colorectal cancer patients.
OncoBEAM™ RAS CRC Kit offers the following advantages: